OCD Research: An Exciting New Study
Do you suffer from OCD? Biohaven Pharmaceuticals is studying an investigational medicine to research potential treatments of OCD.
If you are between the ages of 18 and 65 years old and have been diagnosed with OCD or you think you may have OCD, you may qualify to participate in our OCD research study.
There are medications used to treat OCD. However, some people do not experience relief from OCD symptoms despite being on medication. In this study, adults with OCD who are eligible to participate will receive an investigational medication that is taken in addition to their current medication. This investigational medication targets glutamate, a chemical in the brain that is believed to contribute to OCD. There is no cost to participate, and you may be compensated for your time and travel.
Read what they are saying about the OCD Study in the news.
What is OCD?
Obsessive Compulsive Disorder (OCD) is a mental health disorder that affects 1 in 100 people and occurs when a person gets caught in a cycle of obsessions and compulsions. Obsessions are unwanted, intrusive thoughts, images, or urges that trigger intensely distressing feelings. Compulsions are behaviors an individual engages in to attempt to get rid of the obsessions and/or decrease his or her distress.
Please fill out the form below for more information.
This information will not be shared with anyone except NOCD, Blaze Clinical, and the nearest participating research site.
Biohaven is a clinical-stage pharmaceutical company based in New Haven, Connecticut. We are led by Dr. Vlad Coric, who was an OCD researcher and OCD treating physician at Yale University before joining the pharma industry and ultimately the CEO of Biohaven. We are also a passionate group of dedicated individuals who we come to work each day with a commitment to making a difference in the lives of patients. Meet the Biohaven OCD team and learn a little more about each of us below: